Gas-filled nanobubbles for negatively charged genetic material delivery each includes a lipid membrane defining a gas containing internal void, wherein the lipid membrane includes a plurality of cationic lipids for complexing the negatively charged genetic material, an edge-activator incorporated between lipids of the membrane that enhances the flexibility of the membrane, and a membrane stiffener incorporated on an outer surface of the membrane that enhances the membrane's resistance to tearing.
A fluid circulation device for treating edema of a patient's body limb includes a flexible sleeve having at least one wire and defining a passage for receiving at least a portion of a body limb. At least one motor adjusts tension on the at least one wire for controlling a degree of compression of the sleeve on the at least one portion of the limb.
A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
3.
SYSTEMS, METHODS, AND MEDIA FOR SIMULATING INTERACTIONS WITH AN INFANT
Systems, methods, and media for simulating interactions with an infant are provided. In some embodiments, a system comprises: a display; and at least one processor, wherein the at least one processor is programmed to: receive input to add a state; receive input setting one or more parameters associated with the state; cause content to be presented based on the parameters via the display; save the parameters; cause a simulation to be created; receive a selection of the state; and cause a simulated infant in the simulation to be presented based on the one or more parameters.
An example method includes estimating, by a processor, a spatial position of a portion of an instrument that is adapted to interact with an environmental structure to provide an estimated spatial position for the instrument, in which the spatial position is estimated based on image data that includes at least one image frame of the portion of the instrument and the environmental structure. The method also includes responsive to detecting contact between the instrument and the environmental structure, estimating, by the processor, a measure of force between the instrument and the environmental structure based on the estimated spatial position for the instrument.
A microfluidic device for measuring T cell deformability and/or capillary network occlusion includes at least one microchannel configured to receive a fluid sample containing T cells that flows along a length of the microchannel and includes a plurality of micropillar arrays provided along the length of the microchannel in a direction of fluid flow through the microchannel, wherein each micropillar array defines a plurality of microcapillaries each having a width and the widths of the microcapillaries defined by each micropillar array decreases in a direction of fluid flow through the microchannel.
A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
A method of regenerating an ionic CO2 capture material saturated with CO2 includes applying an electromagnetic field to the ionic CO2 capture material at a frequency and intensity effective for dielectric heating of the ionic CO2 capture material and desorption of captured CO2.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
8.
ISOCITRATE DEHYDROGENASE 1 INHIBITORS AND METHODS OF USE THEREOF
UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (USA)
CASE WESTERN RESERVE UNIVERSITY (USA)
Inventor
Salvino, Joseph
Mohammed, Farheen
Cassel, Joel
Yellamelli, Valli
Winter, Jordan M.
Abstract
The present disclosure provides compounds of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of inhibiting isocitrate dehydrogenase 1 (IDH1) and methods of treating or preventing a disease or disorder using said compounds and/or compositions.
The present disclosure provides compounds of the formula: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods of inhibiting isocitrate dehydrogenase 1 (IDH1) and methods of treating or preventing a disease or disorder using said compounds and/or compositions.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
This disclosure provides an apparatus or system for the modulation of neural activity in the cervical sympathetic chain (CSC) or superior cervical ganglion (SCG) or SCG post-ganglionic branch(es) and for the treatment of sleep apnoea, as well as methods for their use.
University Hospitals Cleveland Medical Center (USA)
Inventor
Hamilton, Jesse
Lima Da Cruz, Gastao
Rajagopalan, Sanjay
Seiberlich, Nicole
Rashid, Imran
Abstract
Methods and systems are provided for cine magnetic resonance fingerprinting (MRF). In one example, a method includes obtaining k-space data of an MRF scan of a subject, the k-space data acquired over a plurality of phases of at least one cardiac cycle of the subject, training an image reconstruction network (IRN) to output, for each phase, one or more subspace images of the subject using the k-space data, and training a parameter estimation network (PEN) to output, for each phase, a set of tissue parameter maps of the subject using the one or more subspace images output by the IRN for the corresponding phase. Upon training the IRN and the PEN, the method further includes obtaining (and displaying and/or saving in memory) a final set of tissue parameter maps of the subject for one or more or each of the plurality of phases.
G01R 33/561 - Image enhancement or correction, e.g. subtraction or averaging techniques by reduction of the scanning time, i.e. fast acquiring systems, e.g. using echo-planar pulse sequences
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
G01R 33/567 - Image enhancement or correction, e.g. subtraction or averaging techniques gated by physiological signals
PSMA targeted compounds, pharmaceutical compositions comprising these compounds, and methods for treating and detecting cancers in a subject are described herein.
A tissue-specific manganese based magnetic resonance imaging (MRI) agent includes the formula: wherein T includes at least one cell specific or tissue specific targeting moiety; C includes at least one pyclen based chelating agent complexed with a Mn ion, and L includes at least one optional linker that covalently links the at least one targeting moiety to the at least one chelating agent.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
CASE WESTERN RESERVE UNIVERSITY (USA)
THE METROHEALTH SYSTEM (USA)
Inventor
Bourbeau, Dennis
Bogie, Kath
Lerchbacker, Joseph
Abstract
An electrode for providing non-invasive genital stimulation for continence of a subject is disclosed. The electrode includes a body and a plurality of projections extending from the body. The body and projections are unitarily formed from a dry, nonmetallic conductive material. The body and projections can be formed by dip molding.
An intratumoral immunotherapy for treating cancer in a subject in need includes a therapeutically effective amounts of cowpea mosaic virus (CPMV), CPMV virus-like particles, potato virus X (PVX), and/or PVX virus-like particles formulated for in situ administration to cancer of the subject, wherein the therapeutically effective amount of CPMV, CPMV virus-like particles, PVX, and/or PVX virus-like particles is an amount effective to provide a durable and systemic anticancer response against cancer metastasis and recurrence in the subject, and the CPMV, CPMV virus-like particles, PVX, and/or PVX virus-like particles are not used as a vehicle for drug or antigen delivery.
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A composition includes a plurality of clot-targeted thrombin cleavable nanoparticles (CTNPs), each CTNP including a thrombin cleavable shell that defines an outer surface of the CTNP, a core, which is loaded with plasmin, and a plurality of platelet binding peptides (PBPs) and fibrin binding peptides (FBPs) that are linked to the shell and extend from the outer surface, wherein the CTNP is configured to adhere to clots, activated platelets, and/or fibrin upon systemic administration to a subject, shield the loaded plasmin in circulation from neutralization, and release the loaded plasmin at the clot site by thrombin triggered degradation of the CTNP.
The present disclosure, in some embodiments, relates to a method for determining a prognosis. The method includes measuring a collagen fiber orientation disorder (CFOD) within a digitized pathology image of a pathology slide corresponding to a patient that has or that has had EOC. A plurality of CFOD features are generated using the measured CFOD. A machine learning model is operated upon the plurality of CFOD features to determine an EOC prognosis for the patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
19.
COMPOSITIONS AND METHODS FOR EXPANDING EX VIVO NATURAL KILLER CELLS AND THERAPEUTIC USES THEREOF
The present disclosure relates to methods for expanding and increasing the cytotoxic activity of natural killer cells comprising co-culturing, as feeder cells, a population of myeloid leukemia cells engineered to express one or more of membrane-bound IL-21 (mbIL-21) or membrane-bound IL-15 (mbIL-15) in the presence of cytokine support. The present disclosure also relates to a population of acute myeloid leukemia cells engineered to express one or more of membrane-bound IL-21 (mbIL-21) or membrane-bound IL-15 (mbIL-15). The present disclosure also relates to methods of treating cancer employing the step of expanding natural killer cells using feeder cells engineered to express one or more of membrane-bound IL-21 (mbIL-21) or membrane-bound IL-15 (mbIL-15).
The present disclosure relates generally to solid particles comprising decellularized cardiac tissue extracellular matrix and, more particularly, to solid particles comprising decellularized cardiac tissue extracellular matrix for use in biomolecule delivery, treatment of cardiac diseases or cardiac conditions, and methods of generating the solid particles.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 9/00 - Drugs for disorders of the cardiovascular system
21.
Intra-perinodular textural transition (ipris): a three dimenisonal (3D) descriptor for nodule diagnosis on lung computed tomography (CT) images
Embodiments classify lung nodules by accessing a 3D radiological image of a region of tissue, the 3D image including a plurality of voxels and slices, a slice having a thickness; segmenting the nodule represented in the 3D image across contiguous slices, the nodule having a 3D volume and 3D interface, where the 3D interface includes an interface voxel; partitioning the 3D interface into a plurality of nested shells, a nested shell including a plurality of 2D slices, a 2D slice including a boundary pixel; extracting a set of intra-perinodular textural transition (Ipris) features from the 2D slices based on a normal of a boundary pixel of the 2D slices; providing the Ipris features to a machine learning classifier which computes a probability that the nodule is malignant, based, at least in part, on the set of Ipris features; and generating a classification of the nodule based on the probability.
A hybrid metamaterial structure includes at least one auxetic portion and at least one non-auxetic portion connected to the auxetic portion. The at least one non-auxetic portion has a nodal honeycomb unit geometry.
The invention described herein provides compositions and methods to culture enteric glial cells, and the associated use of the cultured enteric glial cells.
A method of treating opioid withdrawal and/or dependence in a subject in need thereof, includes administering to the subject a therapeutically effective amount of a composition comprising a D-cysteine ester, a cystine ester, or an adduct, a pharmaceutically acceptable salt, a tautomer, or a solvate thereof.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
CASE WESTERN RESERVE UNIVERSITY (USA)
Inventor
Stavrou, Evi, X.
Abstract
Disclosed herein, are peptides that bind coagulation factor XII (FXII). Also described herein, are methods of administering compounds comprising peptides that bind coagulation FXII to subjects for the treatment of cancer-associated thrombosis, sickle cell disease associated with vaso-occlusive crisis or vascular thrombosis, colon cancer, glioblastoma multiforme, organ fibrosis, Alzheimer's disease, and autoimmune encephalitis.
26.
METHODS AND COMPOSITION OF INHIBITING ASPROSIN MEDIATED OREXIGENESIS AND/OR GLUCOGENSIS
UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (USA)
Inventor
Chopra, Atul
Mishra, Ila
Abstract
A method of inhibiting asprosin mediated orexigenesis and/or glucogenesis in a subject in need thereof includes administering to the subject a therapeutic peptide that includes an amino acid sequence substantially identical to an extracellular portion of the amino acid sequence of protein tyrosine phosphatase receptor type δ (PTPRD) that binds to asprosin.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Wellbore treatment fluids are provided that include an aqueous component and an amphiphilic hyperbranched copolymer comprising the polymerized reaction product of at least a first monomer and a second monomer, where the first monomer comprises at least one surface reactive end group chosen from the group consisting of carboxylates, phosphonates, sulfonates, and zwitterions. Also provided are methods of modifying subsurface energy of a carbonate formation using the wellbore treatment fluids.
The United States Government as Represented by The Department of Veteran Affairs (USA)
Inventor
Chen, Yuli
Li, Haojia
Madabhushi, Anant
Abstract
The present disclosure relate to a method. The method includes accessing segmented digitized pathology imaging data from a cancer patient. The segmented digitized pathology imaging data identifies segmented nuclei, segmented mitosis, and segmented tubule regions. A plurality of nuclear features are extracted using the segmented nuclei. A plurality of mitosis features are extracted using the segmented mitosis. A plurality of tubule features are extracted using the segmented tubule regions. A risk score is generated by operating a machine learning model on the plurality of nuclear features, the plurality of mitosis features, and the plurality of tubule features. The risk score correlates to a risk of recurrence of cancer for the cancer patient.
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A method includes synthesizing covalently bonded lattices based on irreversible bond-making reactions which favor exhaustive substitution on multi-functional substrates, wherein the irreversible bond-making reactions include ordered two-dimensional interfacial polymerizations of a monomer at a liquid/liquid interface, liquid-solid interface, or liquid-gas interface.
C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
C08L 49/00 - Compositions of homopolymers or copolymers of compounds having one or more carbon-to-carbon triple bondsCompositions of derivatives of such polymers
30.
COMPOSITIONS AND METHODS FOR PRESERVING DNA METHYLATION
The disclosure provides methods for storage solutions for preserving DNA methylation patterns over a period of time. The disclosure also provides for methods of using methylated DNA stored in such storage solutions.
The present disclosure relates to a method. The method includes accessing automatically segmented liver data and automatically segmented spleen data from a patient. The automatically segmented liver data is used to determine a liver attenuation and the automatically segmented spleen data is used to determine a spleen attenuation. A liver-to-spleen attenuation ratio is determined from the liver attenuation and the spleen attenuation. A hepatic steatosis determination is made from the liver-to-spleen attenuation ratio
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
32.
COMPOSITIONS AND METHODS FOR PRESERVING DNA METHYLATION
The disclosure provides methods for storage solutions for preserving DNA methylation patterns over a period of time. The disclosure also provides for methods of using methylated DNA stored in such storage solutions.
The present disclosure, in some embodiments, relates to a method of mitigating domain shift. The method includes accessing a first imaging data set having one or more first images from a first site and accessing a second imaging data set having one or more second images from a second site. The one or more first images respectively include a first on-target region. The one or more second images respectively include a second off-target region. The first on-target region is modified using the second off-target region to generate a calibrated first on-target region. The calibrated first on-target region has a first domain shift with respect to the second off-target region and the first on-target region has a second domain shift with respect to the first on-target region. The first domain shift is smaller than the second domain shift.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
34.
INTACT MASS SPECTROMETRY FOR DIRECT PROTEIN FOOTPRINTING DOSIMETRY USING COVALENT LABELING
The present disclosure provides a protein footprinting method based on mass spectrometry of an intact protein labeled with covalent labeling reagents, including hydroxyl radicals. The method involves intact MS screening of labeled samples and measurement of the extent of observed labeling (e.g., average oxidation events per protein) from the intact mass spectra. Advantageously, this direct, intact mass spectrometry-based approach can be used to determine a suitable dose range of the labeling agent relative to a subject protein in order to produce adequately labeled protein while avoiding damage to the subject protein caused by excessive use of the labeling agent.
The invention described herein provides an improved method and reagents to isolate nuclear RNA from high degradation tissues, such as duodenum, for use in, for example, high resolution transcriptome profiling and analysis.
36.
PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND THEIR USES
A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of a compound, the small molecule having a general formula: A-L-X—Z (I).
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
37.
PSMA TARGETED ANTICANCER AGENT-PHTHALOCYANINE CONJUGATE COMPOUNDS AND USES THEREOF
PSMA targeted anticancer agent-phthalocyanine conjugate compounds, pharmaceutical compositions comprising these compounds, methods for treating and detecting cancers in a subject.
A re-usable wearable device includes a flexible PCB having a re-sizable hand portion with an attachment mechanism and at least one re-sizable digit portion. Each of the re-sizable digit portions includes at least one electrode connected to the flexible PCB by an adjustable electrode holder. Each electrode is positioned in close contact with the skin to provide electrical stimulation causing a referred sensation in another portion of the hand. Each electrode holder includes a setting with a track and anchoring mechanism for positioning the electrode at a radial position on the digit. The device can include sensors to measure the position and movements of the hand to augment or replace optical hand tracking information. The wearable device can provide referred sensation via electrical stimulation and improved position information.
A method of detecting drug-resistant cancer in a subject is described. The method includes contacting a tissue of the subject with an effective amount of a molecular probe, detecting the amount of the molecular probe present in the tissue, comparing the amount of molecular probe detected to a control value, and detecting drug-resistant cancer in the subject if the amount of the molecular probe present in the tissue is higher than the control value. The molecular probe includes the following formula: P-L-C wherein P is a EDB-FN targeting peptide, C is a contrast agent; and L is a non-peptide linker that covalently links the peptide to the contrast agent. Methods of monitoring the treatment of drug resistant cancer are also described.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
CASE WESTERN RESERVE UNIVERSITY (USA)
Inventor
Bogie, Katherine M.
Abstract
Risk of pressure injuries can be assessed by detecting, in a biological sample, a respective level of at least one biomarker associated with pressure injuries. The biological sample can be, for example, whole blood or other bodily fluids. The at least one biomarker can comprise fatty acid binding protein-3 (FABP3) and/or fatty acid binding protein-4 (FABP4). The biomarkers can be detected by reverse transcription loop-mediated isothermal amplification (RT-LAMP) methods. The biomarkers can be detected by a microfluidics-based biochip.
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventor
Chen, Yuanyuan
Palczewski, Krzysztof
Abstract
A method of treating an inherited ocular disorder associated with or caused by a misfolded ocular protein in a subject in need thereof includes administering to the subject a compound that promotes clearance of misfolded ocular protein.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A high throughput assay for screening hemoglobin oxygen affinity modifying agents, the assay includes a well plate configured to receive samples of hemoglobin, red blood cells, or a blood sample that has been deoxygenated and at least one oxygen affinity modifying agent; a UV-VIS spectroscopic microplate reader that is configured to determine an optical signature of hemoglobin, red blood cells, or blood in each well of the well plate; and a processor configured for comparing the determined optical signature to a control optical signature in each of the wells wherein differences between the determined optical signature and the control optical signature is indicative of the agents' effect on hemoglobin oxygen affinity.
A method of treating an ocular disorder, such as light induced retinal degeneration, macular degeneration, Stargardt's disease, geographic atrophy, and retinitis pigmentosa, in a subject in need thereof, includes administering to the subject a therapeutically effective amount of a compound of formula (I), a 3-(cyclohexylmethoxy)-benzaldehyde moiety connected to a gamma-hydroxyamine moiety, which may be fluoro-substituted, as a retinoid isomerase (RPE65) inhibitor, or a pharmaceutically acceptable salt, tautomer, or solvate thereof.
C07C 211/28 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by unsaturated carbon chains
C07C 215/20 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
45.
ADOPTIVE IMMUNOTHERAPY COMPOSITIONS AND METHODS OF TRACKING
An adoptive immunotherapy composition includes an enriched population of immune cells, wherein at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, or more immune cells include intracellular nanobubbles.
A synthetic lentiviral vector construct comprises a genomic RNA packaging enhancer (GRPE) element and lentiviral nucleic acid sequences sufficient for reverse transcription and packaging in a host cell.
A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor, and/or PKM2 inhibitor.
A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
A61K 31/424 - Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
48.
SYSTEM AND METHOD FOR UNSUPERVISED SEGMENTATION OF IMAGES USING MAGNETIC RESONANCE FINGERPRINTING
A method for generating segmented images of a region of interest of a subject using magnetic resonance fingerprinting (MRF) includes receiving MRF data and a plurality of quantitative parameter maps generated using the MRF data, deriving a first set of image features based on the plurality of quantitative parameter maps and the MRF data, performing unsupervised clustering on each image feature in the first set of image features to generate a first set of clusters, determining a loss for each image feature and the associated cluster for the image feature, selecting a second set of image features based on the determined loss for each image feature, performing unsupervised clustering on the second set of image features to produce a second set of clusters, generating a non-background cluster with low probability voxels, and generating a segmented image based on the second set of clusters and the non-background cluster.
A method for reconstructing images using a self-calibrated subspace reconstruction includes receiving data acquired from a subject using a magnetic resonance imaging (MRI) system, generating aliasing-free low resolution images from at least a portion of the received data using temporally local low-rank matrix completion, estimating a temporally global subspace using the aliasing-free low resolution images, and generating aliasing-free high resolution images from the received data using temporally global subspace reconstruction that utilizes the estimated temporally global subspace. In some embodiments, a customized outlier detection algorithm can then be used to detect measurement errors in the aliasing-free high resolution images and to correct the aliasing-free high resolution images. Aliasing-free T1, T2, and ADC maps may be generated after comparing the corrected aliasing free high resolution images with a dictionary.
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/563 - Image enhancement or correction, e.g. subtraction or averaging techniques of moving material, e.g. flow-contrast angiography
G01R 33/565 - Correction of image distortions, e.g. due to magnetic field inhomogeneities
G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting
A method for generating magnetic resonance (MR) images using a magnetic resonance imaging (MRI) system includes determining an optimized set of sequence parameters for a pulse sequence using an optimization framework comprising a systematic error index (SEI) configured to characterize errors, performing, using the MRI system, the pulse sequence comprising the optimized set of sequence parameters to acquire data from a subject, and generating at least one image of the subject using the acquired data.
The invention described herein provides compositions and methods to maintain astrocytes in resting, enrichment and/or maturation, or activation states so that potential therapeutic agents treating diseases or conditions associated with reactive astrocytes can be identified.
A wearable human-machine interface device includes a base, a finger, a sensor, and an interface controller. The finger extends longitudinally from the base and including first and second rigid finger segments. A proximal end of the first finger segment is coupled to the base, and a proximal end of the second finger segment is coupled to a distal end of the first finger segment by a joint. The joint is adapted to enable rotational movement of the second finger segment relative to the first finger segment. The sensor is coupled to the finger and configured to provide a sensor signal representative of a position and/or movement of the second finger segment relative to the first finger segment. An interface controller is configured to provide a control signal representative of a flexion of the finger and/or a position of a fingertip of the finger based on the sensor signal.
Multi-modal neuromodulation applied to an autonomic nerve using a multicontact electrode can upregulate a portion of the autonomic nervous system and downregulate another portion of the autonomic nervous system to affect a physiological condition. A generator can generator and provide a neuromodulation signal and another neuromodulation signal, each having at least one parameter, to the electrode. The neuromodulation signal can be applied at a time and the other neuromodulation signal can be applied at another time to balance sympathetic and parasympathetic activity. A sensor can record a physiological parameter related to physiological condition and a controller can receive the recoding and can adjust which neuromodulation signal is applied and/or at least one of the parameters of the neuromodulation signal or the other neuromodulation signal based on the recording of the physiological parameter.
A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising an glutathione alkyl ester, adduct thereof, or pharmaceutically acceptable salt, tautomer, or solvate thereof.
The United States as represented by the Department of Veterans Affairs (USA)
Inventor
Majerus, Steve Ja
Dunning, Jeremy
Bogie, Katherine M.
Potkay, Joseph A.
Abstract
A sensor apparatus includes at least one substrate layer of an elastically deformable material, the substrate layer extending longitudinally between spaced apart ends thereof. A conductive layer is attached to and extends longitudinally between the spaced apart ends of the at least one substrate layer. The conductive layer includes an electrically conductive material adapted to form a strain gauge having an electrical resistance that varies based on deformation of the conductive layer in at least one direction.
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
G01L 9/06 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means by making use of variations in ohmic resistance, e.g. of potentiometers of piezo-resistive devices
56.
MAJOR ADVERSE CARDIOVASCULAR EVENT RISK PREDICTION BASED ON COMPREHENSIVE ANALYSIS OF CT CALCIUM SCORE EXAM
Systems, methods, and apparatus are provided for determining a risk prediction for major adverse cardiovascular event (MACE) for a patient based on a computed tomography (CT) calcium score image of the patient's chest. In one example, a method includes receiving a computed tomography (CT) calcium score image of a chest; identifying tissue of interest in the CT calcium score image; analyzing the CT calcium score image to determine features of the identified tissue of interest; and determining a risk prediction of MACE based on the features.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
57.
CATHETER MAGNETIC ACTUATION AND INSERTION CONTROL, CATHETER LOCALIZATION AND CONTACT FORCE ESTIMATION, AND/OR MAGNETICALLY ACTUATED CATHETER WITH STIFFENING ELEMENT TO CONTROL DEFLECTION
This disclosure relates to catheter magnetic actuation and insertion control, catheter localization (e.g., tracking) and contact force estimation, and/or magnetically actuated catheters with a variable stiff segment. The systems, devices and methods herein can include or be used in conjunction with interventional magnetic resonance imaging (MRI). A method includes determining an axial position of a distal portion of a device based on position data, in which the position data is representative of a spatial position of at least a flexible distal portion of the device, and the device includes at least one actuation coil at a distal portion of the device. The method also includes determining an actuation control signal to provide current to the at least one coil to deflect the distal portion of the device based on the position data and target data, in which the target data is representative of at least one of a location of a target site and a trajectory of the distal portion of the device to the target site.
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 5/06 - Devices, other than using radiation, for detecting or locating foreign bodies
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
In one example, a system includes a catheter having an elongate catheter body extending between a proximal end portion and a distal end portion. A coil is disposed on a flexible body portion of the catheter body and configured to deflect the flexible body portion based on magnetic flux generated responsive to a current applied to the coil and an external magnetic field. An actuation control circuitry is coupled to the coil and configured to provide the current. The current has a magnitude, direction and duty cycle, and the actuation control circuitry is configured to control at least one of the magnitude, the direction and the duty cycle of the current based on a current command signal to control a magnitude and/or a direction of deflection for the flexible body portion.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/α4β1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing α4ρ1.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/663 - Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 41/17 - Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
60.
COMPOSITIONS AND METHODS FOR MODULATING HEXIM1 EXPRESSION
A method of inducing HEXIM1 expression in cells of a subject includes administering to the cells a compound having the formula,
A method of inducing HEXIM1 expression in cells of a subject includes administering to the cells a compound having the formula,
A method of inducing HEXIM1 expression in cells of a subject includes administering to the cells a compound having the formula,
and pharmaceutically acceptable salts thereof.
Subcutaneous photobiomodulation (PBM) is described for treatment of one or more medical conditions, including pulmonary fibrosis, an abnormality in upper airway function, hypertension, congestive heart failure, pulmonary hypertension, etc. The system includes a light source that can generate light inside the body (subcutaneously), a light transmission medium to transmit the light to an emitter, and the emitter sized and shaped to deliver the light directly to a target area associated with pulmonary fibrosis, an abnormality in upper airway function, hypertension, congestive heart failure, and/or pulmonary hypertension.
Described herein are systems and methods for the treatment of pain using electrical nerve conduction block (ENCB). Contrary to other methods of pain treatment, the ENCB can establish a direct block of neural activity, thereby eliminating the pain. Additionally, the ENCB can be administered without causing electrochemical damage. An example method can include: placing at least one electrode contact in electrical communication with a region of a subject's spinal cord; applying an electrical nerve conduction block (ENCB) to a nerve in the region through the at least one electrode contact; and blocking neural activity with the ENCB to reduce the pain or other unwanted sensation in the subject.
The United State Government as Represented by the Department of Veteran Affairs (USA)
Inventor
Xiong, Wen-Cheng
Mei, Lin
Chen, Li
Xiong, Lei
Abstract
A method of treating Alzheimer's disease (AD) in a subject includes administering to the subject a therapeutically effective amount of at least one parathyroid hormone type 1 receptor (PTH1R) agonist.
A61K 38/29 - Parathyroid hormone, i.e. parathormoneParathyroid hormone-related peptides
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A biphasic osteotendinous repair scaffold is disclosed. The biphasic osteotendinous repair scaffold comprises a first phase comprising electrochemically aligned collagen (ELAC) threads and a calcium phosphate mineral and having a major surface. The biphasic osteotendinous repair scaffold also comprises a second phase comprising ELAC threads and having a major surface. The ELAC threads of the first phase are braided and crosslinked. The ELAC threads of the second phase are braided and crosslinked. The ELAC threads of the first and second phases form first and second interconnected macroporosities throughout the first and second phases, respectively. The calcium phosphate mineral of the first phase is distributed on the major surface of the first phase and within the interconnected macroporosity of the first phase. The second phase is adjacent to the first phase.
A61L 27/46 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
65.
TARGETING B CELL ACTIVATING FACTOR RECEPTOR (BAFF-R) USING LIGAND-BASED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS
The disclosure relates generally to ligand-based chimeric antigen receptor (CAR) cells. More specifically, the CAR cells express B-cell activating factor (BAFF) protein for recognition by a receptor of BAFF on the surface of a cell. CAR cells can include cytotoxic T lymphocytes, natural killer (NK) cells or natural killer T (NKT) cells that express a chimeric receptor that recognizes a receptor of BAFF. The disclosure further relates to methods of treating a variety of conditions, such as cancers and autoimmune diseases, using the disclosed CAR cells.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A textile-based sensor includes a textile triboelectric nanogenerator sensor attached to and overlying a textile piezoresistive sensor, wherein the textile triboelectric nanogenerator sensor is configured to generate an electrical signal indicative of object contact force and/or frequency with the textile triboelectric nanogenerator sensor, object material, and object surface morphology or texture, and the textile piezoresistive sensor is configured to generate an electric signal indicative of the applied external pressure to the sensor, wherein the textile triboelectric nanogenerator sensor overlies the textile piezoresistive sensing.
G01L 1/22 - Measuring force or stress, in general by measuring variations in ohmic resistance of solid materials or of electrically-conductive fluidsMeasuring force or stress, in general by making use of electrokinetic cells, i.e. liquid-containing cells wherein an electrical potential is produced or varied upon the application of stress using resistance strain gauges
G01L 1/18 - Measuring force or stress, in general using properties of piezo-resistive materials, i.e. materials of which the ohmic resistance varies according to changes in magnitude or direction of force applied to the material
A chimeric antigen receptor (CAR) includes an extracellular antigen binding domain, wherein the extracellular antigen binding domain comprises a polypeptide that binds to an oncostatin-M receptor (OSMR), leukemic inhibitory factor receptor (LIFR), a heterodimer between transmembrane glycoprotein 130 (gp130) receptor and OSMR, and/or heterodimer between gp130 receptor and LIFR.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
A method of treating cancer in a subject that includes administering to the cancer a therapeutically effective amount of an anti-cancer virus particle, the virus particle including a rod-shaped plant virus or virus-like particle and mitoxantrone (MTO) or analogs thereof, wherein the MTO is loaded into the interior channel of the rod-shaped plant virus particle.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of a small molecule agonist of EphA2 receptor protein, the small molecule having a general formula: A-L-X-Z (I).
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Systems, methods, and media for displaying interactive augmented reality presentations are provided. In some embodiments, a system comprises: a head mounted display comprising: a transparent display; a plurality of sensors; and at least one processor, wherein the at least one processor is programmed to: select a content display location of a plurality of predetermined content display locations to use to present content based at least in part on a location of the head mounted display within a current physical environment; and cause content to be presented by the head mounted display anchored at the selected content display location.
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G06F 3/0346 - Pointing devices displaced or positioned by the userAccessories therefor with detection of the device orientation or free movement in a 3D space, e.g. 3D mice, 6-DOF [six degrees of freedom] pointers using gyroscopes, accelerometers or tilt-sensors
A system to treat a target area of a patient's brain can include at least one external electro-optical applicator and at least one window spanning beneath skin covering a skull of the patient and through obstructive material of the skull of the patient. Each electro-optical applicator can include at least one light source and at least one electrical source. Each window can include at least one electrode proximal the target area and a conductive path to the at least one electrode. The at least one window can be configured to: transmit a light signal from the at least one light source through the window to the target area of the brain of the patient; and deliver an electrical modulation from the at least one electrical source via the at least one electrode to the target area.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
CASE WESTERN RESERVE UNIVERSTIY (USA)
Inventor
Triolo, Ronald J.
Audu, Musa L.
Makowski Nathaniel S.
Abstract
Methods, systems, and/or apparatuses are described for providing electrical stimuli and motorized assistance for leg movement of a user. A quantity of electrical stimuli may be provided to a portion of a paretic leg during the first step of a walking motion. Motorized assistance at a quantity of torque may be provided to the portion of the paretic leg during the first step of the walking motion. Data associated with the paretic leg during the first step of the walking motion may be received. Based on the data, the deviation of the paretic leg, during the first step of the walking motion, from the target configuration for the paretic leg may be determined. The quantity of electrical stimuli during the next step of the walking motion for the paretic leg may be modified.
A pepino mosaic virus (PepMV) carrier comprising a PepMV particle that has been modified to carry an imaging agent or anticancer agent is described. The PepMV carrier can be used in a method of targeting cancer cells and tissue by administering it to a subject. Cancer tissue targeted by the PepMV carrier can be imaged using an imaging agent, or treated using an anticancer agent.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Systems, methods, and media for presenting biophysical simulations in an interactive mixed reality environment are provided. In some embodiments, a system comprises: a head mounted display comprising: a transparent display; sensors; and a processor programmed to: receive medical imaging data associated with a subject; receive, from a server, information useable to visualize a simulation of biophysical processes and a subject-specific anatomical model based on the medical imaging data; cause a visualization of the simulation to be presented, via the transparent display, in connection with the medical imaging data and an instrument in a first position; receive, from the server, updated information useable to visualize an updated simulation with the instrument in a second position; and cause a visualization of the updated simulation to be presented with the instrument presented in the second position.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
77.
TREATMENT OF CHRONIC PAIN VIA DIRECT PHOTOBIOMODULATION OF A NERVE
Direct photobiomodulation (PBM) refers to applying PBM directly to a nerve of interest. Dosages of direct PBM can be configured by a controller/energy source located outside the body and delivered by an emitter implanted within the body proximal to at least one sensory/sensorimotor nerve for chronic pain management. The at least one dose of PBM can be applied for a time to selectively inhibit conduction of signals indicative of pain in at least one small diameter sensory nerve fiber without affecting conduction of at least one larger diameter nerve fiber within the at least one sensory and/or sensorimotor nerve. Then conduction in the small diameter sensory fiber(s) remains blocked for another time (at least a day longer than the time), thereby stopping pain for at least the other time.
A chimeric antigen receptor (CAR) for NK cells includes an extracellular antigen binding domain, a transmembrane domain, and at least one an intracellular signaling domain.
A composition for use in promoting accumulation and/or uptake of a systemically delivered therapeutic agent and/or diagnostic agent in a heart of a subject in need thereof includes administering a plurality of poly(L-lactic co-glycolic acid) (PLLGA) nanoparticles effective to promote accumulation and/or uptake of the therapeutic agent and/or diagnostic agent in the heart.
An anticancer peptide conjugate is described that comprises the following formula: P-L-A wherein: P is a peptide that includes an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, or variants thereof in which one or more L-amino acids have been replace with a corresponding D-amino acid; A is an antitumor agent; and L is an optional linker that covalently links the peptide to the antitumor agent, and pharmaceutically acceptable salts thereof. Methods of using the anticancer peptide conjugates to treat cancer are also described.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A method for suppressing body weight gain, reducing body weight, or preventing, alleviating, or treating obesity in a subject in need thereof includes administering to the subject a therapeutically effective amount of a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, and/or SCoR inhibitor.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
82.
INDOLE, DERIVATIVES, AND USES IN REPRODUCTIVE MEDICINE
Disclosed herein are methods of isolating an oocyte or ovum for use in in vitro fertilization comprising contacting a sample comprising an oocyte or ovum with indole or a derivative providing an indole preserved oocyte or ovum. In certain embodiments, this disclosure relates to compositions for preserving or culturing oocytes or ova for further use in reproductive medicine.
The United States Government as Represented by The Department of Veteran Affairs (USA)
Inventor
Madabhushi, Anant
Monabbati, Shayan
Bera, Kaustav
Abstract
The present disclosure, in some embodiments, relates to a method. The method includes accessing one or more digitized pathology images of a cell cluster area comprising epithelial cells obtained from a bile duct of a patient having a bile duct stricture. The cell cluster area is segmented to identify segmented nuclei and non-nuclei regions. A plurality of texture features are extracted from the segmented nuclei and the non-nuclei regions. A plurality of nuclear shape features are extracted from the segmented nuclei. The plurality of nuclear shape features and the plurality of texture features are provided to a machine learning model configured to generate a cytological diagnosis of the epithelial cells within the cell cluster area.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
84.
SYSTEM AND METHOD FOR OPTICAL DETECTION OF HEMOGLOBIN VARIANTS, OXYGEN AFFINITY, AND DEOXYGENATION
A method of determining at least one of hemoglobin oxygen affinity, rate of hemoglobin deoxygenation, or the presence of hemoglobin variants in blood of a subject, the method includes determining differences of absorption spectra of oxygenated and deoxygenated hemoglobin, red blood, and/or blood obtained from the subject and comparing the determined absorption spectra differences to a control value, wherein the absorption spectra differences are indicative of hemoglobin oxygen affinity, rate of hemoglobin deoxygenation, or the presence of hemoglobin variants in the blood of the subject.
UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER (USA)
Inventor
Marks, Jeffrey
Schomisch, Steve
Abstract
A device for bypassing an enterocutaneous fistula in a patient includes a flexible tube extending from a first axial end to a second axial end and defining a passage extending the entire length of the tube, inflatable cuffs located at each of the first axial end and the second axial end of the tube, the inflatable cuffs configured to seal the first axial end and the second axial end to the internal wall of a bowel, at least one inflation tube fluidly connected to the inflatable cuffs for supplying inflation liquid to and from the inflatable cuffs, the inflatable cuffs are configured to inflate to a fluid pressure effective to create a fluid seal to the internal wall of the bowel.
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
86.
RADIOMICS SIGNATURES FOR PATHOLOGIC CHARACTERIZATION OF STRICTURES ON MR AND CT ENTEROGRAPHY
The present disclosure, in some embodiments, relates to a non-transitory computer-readable medium storing computer-executable instructions that, when executed, cause a processor to perform operations, including accessing an imaging data set having one or more radiological images of a patient having Crohn's disease, the one or more radiological images including one or more intestinal strictures; identifying a plurality of determinative features from within the one or more intestinal strictures in the one or more radiological images, the plurality of determinative features being associated with one or more pathological features used to identify inflammation or fibrosis within an intestinal stricture; and applying a machine learning model to the plurality of determinative features to identify an extent of inflammation or fibrosis within the one or more intestinal strictures.
G06V 10/44 - Local feature extraction by analysis of parts of the pattern, e.g. by detecting edges, contours, loops, corners, strokes or intersectionsConnectivity analysis, e.g. of connected components
87.
PROCESSES FOR PRODUCING AND REPROCESSING A RECYCLABLE ETHYLENE-VINYL ESTER POLYMER
This invention relates to a process for producing a recyclable ethylene-vinyl ester polymer comprising reacting an ethylene-vinyl ester polymer having an irreversibly crosslinked structure with a poly(vinyl alcohol) (PVA), via a transesterification reaction, in the presence of a transesterification catalyst, to produce a recyclable ethylene-vinyl ester vitrimer. This invention also relates to a recyclable ethylene-vinyl ester vitrimer prepared according to the process.
BOSTON SCIENTIFIC NEUROMODULATION CORPORATION (USA)
CASE WESTERN RESERVE UNIVERSITY (USA)
Inventor
Jenkins, Michael
Zhuo, Junqi
Moffitt, Mchael, A.
Howard, Joshua, Dale
Zhu, Changfang
Abstract
An optical lead can include a cuff body having an exterior surface and an interior surface, wherein the cuff body defines a nerve channel for receiving a portion of a nerve; a lead body coupled, or coupleable, to the cuff body; at least one light emitter disposed on or within the cuff body or the lead body; and at least one reflective element disposed on, within, or beneath the interior surface of the cuff body, wherein the at least one reflective element is configured to reflect light emitted from the at least one light emitter. Alternatively or additionally, the cuff lead can include a receptacle for removably receiving a distal end portion of the lead body. Another system includes a cuff body with at least one light emitter, an electronic subassembly for operation, and an antenna to receive power from an external source.
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
C07D 209/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
90.
METHOD FOR GENERATING ONE OR MORE STRAIN MEASUREMENTS ASSOCIATED WITH A BIOLOGICAL SURFACE
The United States as represented by the Department of Veterans Affairs (USA)
Inventor
Majerus, Steve Ja
Dunning, Jeremy
Bogie, Katherine M.
Potkay, Joseph A.
Abstract
A sensor apparatus includes at least one substrate layer of an elastically deformable material, the substrate layer extending longitudinally between spaced apart ends thereof. A conductive layer is attached to and extends longitudinally between the spaced apart ends of the at least one substrate layer. The conductive layer includes an electrically conductive material adapted to form a strain gauge having an electrical resistance that varies based on deformation of the conductive layer in at least one direction.
G01L 9/00 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means
G01L 9/06 - Measuring steady or quasi-steady pressure of a fluid or a fluent solid material by electric or magnetic pressure-sensitive elementsTransmitting or indicating the displacement of mechanical pressure-sensitive elements, used to measure the steady or quasi-steady pressure of a fluid or fluent solid material, by electric or magnetic means by making use of variations in ohmic resistance, e.g. of potentiometers of piezo-resistive devices
91.
OPTICAL MODULATION CUFF DEVICES, SYSTEMS, AND METHODS OF MAKING AND USING
Boston Scientific Neuromodulation Corporation (USA)
Case Western Reserve University (USA)
Inventor
Jenkins, Michael
Zhuo, Junqi
Moffitt, Michael A.
Howard, Joshua Dale
Zhu, Changfang
Abstract
An optical lead can include a cuff body having an exterior surface and an interior surface, wherein the cuff body defines a nerve channel for receiving a portion of a nerve; a lead body coupled, or coupleable, to the cuff body; at least one light emitter disposed on or within the cuff body or the lead body; and at least one reflective element disposed on, within, or beneath the interior surface of the cuff body, wherein the at least one reflective element is configured to reflect light emitted from the at least one light emitter. Alternatively or additionally, the cuff lead can include a receptacle for removably receiving a distal end portion of the lead body. Another system includes a cuff body with at least one light emitter, an electronic subassembly for operation, and an antenna to receive power from an external source.
The disclosure provides methods for identifying genomic loci (e.g., vimentin and/or SqBE18) that are differentially methylated in metaplasias (e.g., Barrett's esophagus) and/or neoplastic cancers (e.g., esophageal cancers). Identification of methylated genomic loci has numerous uses, including for example, to characterize disease risk, to predict responsiveness to therapy, to non-invasively diagnose subjects and to treat subjects determined to have gastrointestinal metaplasias and/or neoplasias.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
94.
COMPOSITIONS AND METHODS OF TREATING USHER SYNDROME III
An isolated polynucleotide includes a nucleic acid sequence that includes a cDNA coding sequence of a clarin-1 gene and a 3′UTR nucleic acid that is derived from the 3′UTR of the clarin-1 gene. The 3′UTR nucleic acid can enhance expression of clarin-1 in a cell transfected with the polynucleotide compared to a cell transfected with a similar polynucleotide devoid of the 3′UTR nucleic acid.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
Bladder events can be classified and output to a neuromodulation system to control at least one bladder function. A sensing device in a bladder can sense vesical pressure events, which can be classified by a signal processing device. An event of the vesical pressure data sample can be input into a buffer with past samples, a multi-level discrete wavelet transform can be applied to the samples to output approximation and detail coefficient arrays. Statistical features can be extracted using the approximation and detail coefficient arrays and a portion of the samples. A neural network can compute a vector of probabilities from the statistical features and the event can be labeled based on the vector of probabilities. The event can be an abdominal event, a detrusor overactivity event, no event, or a voiding bladder contraction event, which can be input into the neuromodulation system.
Board of Regent of the University of Texas System (USA)
Inventor
Markowitz, Sanford
Ready, Joseph
Zhang, Yongyou
Antczak, Monika
Willson, James K.V.
Posner, Bruce
Greenlee, William
Abstract
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A triboelectric-electromagnetic hybrid nanogenerator (TEHG) includes a ball-based triboelectric nanogenerator (TENG) and an electromagnetic generator (EMG) configured to move due to exterior fluid movement to generate triboelectric and electromagnetic charging for harvesting wave energy.
F03B 13/20 - Adaptations of machines or engines for special useCombinations of machines or engines with driving or driven apparatusPower stations or aggregates characterised by using wave or tide energy using wave energy using the relative movement between a wave-operated member and another member wherein both members are movable relative to the sea bed or shore
99.
TUNABLE, STABLE SCLEROSING FOAM FOR VASCULAR INTERVENTIONS
A sclerosing foam includes a liquid phase and a gas phase, wherein the liquid phase comprises at least one sclerosing agent and the gas phase comprises at least about 50% by volume of a pefluorocarbon gas.
A method of accelerating cellular maturation is provided, the method including impairing the activity of developmental transcriptional condensates at an intermediate stage of a cell lineage. Specifically, Sox6 gene expression is inhibited to accelerate maturation of oligodendrocyte precursors, such as oligodrendrocyte progenitor cells (OPCs), into fully mature myelin-producing oligodendrocytes.
